These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 21198858

  • 21. [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
    Bai CM, Yang T, Xü Y, Zhang W, Liu XL, Zhu YL, Chen SC, Shen T.
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):142-4. PubMed ID: 16750023
    [Abstract] [Full Text] [Related]

  • 22. Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
    Troutaud D, Petit B, Bellanger C, Marin B, Gourin-Chaury MP, Petit D, Olivrie A, Feuillard J, Jauberteau MO, Bordessoule D.
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):118-24. PubMed ID: 20371444
    [Abstract] [Full Text] [Related]

  • 23. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [Abstract] [Full Text] [Related]

  • 24. Standard treatment of advanced-stage diffuse large B-cell lymphoma.
    Coiffier B.
    Semin Hematol; 2006 Oct; 43(4):213-20. PubMed ID: 17027655
    [Abstract] [Full Text] [Related]

  • 25. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A.
    Clin Cancer Res; 2007 Apr 01; 13(7):2226-35. PubMed ID: 17404107
    [Abstract] [Full Text] [Related]

  • 26. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Prat J, Sierra J.
    Ann Hematol; 2006 Sep 01; 85(9):597-603. PubMed ID: 16830142
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
    Visco C, Canal F, Parolini C, Andreoli A, Ambrosetti A, Krampera M, Lestani M, Pizzolo G, Chilosi M.
    Haematologica; 2006 May 01; 91(5):687-90. PubMed ID: 16670073
    [Abstract] [Full Text] [Related]

  • 29. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
    Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH, Kim SW, Park BH, Yoon SO, Huh J, Lee SW, Suh C.
    Eur J Haematol; 2010 Aug 01; 85(2):149-57. PubMed ID: 20477862
    [Abstract] [Full Text] [Related]

  • 30. Diffuse large B-cell lymphoma with fibrillary matrix.
    Dargent JL, Meiers I, Lespagnard L, Ma Y, Dehou MF, Verhest A.
    Diagn Cytopathol; 2002 Oct 01; 27(4):223-6. PubMed ID: 12357500
    [Abstract] [Full Text] [Related]

  • 31. Centroblastic diffuse large B cell lymphoma displays distinct expression pattern and prognostic role of apoptosis resistance related proteins.
    Faccion RS, Rezende LM, Romano Sde O, Bigni Rde S, Mendes GL, Maia RC.
    Cancer Invest; 2012 Jun 01; 30(5):404-14. PubMed ID: 22571341
    [Abstract] [Full Text] [Related]

  • 32. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
    Eser B, Sari I, Canoz O, Altuntas F, Cakmak E, Ozturk A, Ozkan M, Er O, Cetin M, Unal A.
    Am J Hematol; 2006 May 01; 81(5):307-14. PubMed ID: 16628716
    [Abstract] [Full Text] [Related]

  • 33. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma.
    Alas S, Ng CP, Bonavida B.
    Clin Cancer Res; 2002 Mar 01; 8(3):836-45. PubMed ID: 11895917
    [Abstract] [Full Text] [Related]

  • 34. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S, Hansson U, Olsson M, Torén L, Bergström A, Nilsson-Ehle H, Andersson PO.
    Br J Haematol; 2010 May 01; 149(4):560-8. PubMed ID: 20201946
    [Abstract] [Full Text] [Related]

  • 35. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.
    Ai Zheng; 2006 Dec 01; 25(12):1543-9. PubMed ID: 17166383
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.
    Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken JH, Jiwa NM, Jansen PM, Kluin-Nelemans HC, Ossenkoppele GJ, Gundy C, Meijer CJ, Oudejans JJ.
    Blood; 2005 Apr 01; 105(7):2916-23. PubMed ID: 15576477
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type.
    Boelens J, Jais JP, Vanhoecke B, Beck I, Van Melckebeke H, Philippé J, Bracke M, Jardin F, Brière J, Leroy K, Offner F, Lust S.
    Leuk Res; 2013 Jan 01; 37(1):3-8. PubMed ID: 22938940
    [Abstract] [Full Text] [Related]

  • 40. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
    Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A.
    Mol Cancer Ther; 2005 Jan 01; 4(1):13-21. PubMed ID: 15657349
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.